Resistance Training May Reverse Biological Aging in Cancer Survivors

A recent pilot study published in the journal *Cancers* suggests that resistance training offers benefits for cancer survivors that extend well beyond physical strength. While exercise is commonly prescribed to combat treatment-related fatigue and muscle loss, this research indicates that a consistent 10-week weightlifting program may actually help reverse markers of accelerated biological aging caused by chemotherapy and stem cell transplants.

The study followed eight cancer survivors and eight healthy controls, tracking changes in immune function, DNA methylation, and gut microbiome health. Prior to the intervention, survivors exhibited signs of premature aging, including elevated systemic inflammation and a depletion of naïve T cells—the immune cells responsible for identifying new pathogens. Following the 10-week regimen, these biological disparities between the survivors and the control group significantly diminished, suggesting that resistance training can help restore a more youthful immune profile.

Perhaps most encouraging is the finding that cancer survivors achieved strength gains comparable to the healthy control group, with both cohorts increasing their training volume by approximately 150%. This challenges the clinical assumption that past cancer treatments permanently limit the body's capacity to adapt to physical stress. Furthermore, participants experienced favorable shifts in body composition, characterized by a reduction in fat mass and the preservation of lean muscle.

These findings have significant implications for post-cancer care, highlighting the importance of accessible, personalized strength training as a tool for long-term recovery. By utilizing a model that emphasizes supervised group sessions in standard gym environments, the study provides a scalable framework for survivors to improve their biological resilience. Ultimately, this research underscores that resistance training is not merely a fitness goal, but a vital therapeutic intervention for mitigating the long-term physiological toll of cancer treatment.